🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 40% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size
20 Servings
Other Combinations Product Type
40% Evidence Coverage

Supplement Facts — Evidence Check

Calories
10 Calorie(s)
Total Fat
1 Gram(s) (1% DV)
12 mg (75% DV)
✅ Within RDA (0.9× RDA of 14 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 12mg UL 35mg
1000 mcg (41667% DV)
📊 416.7× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 1.0mg
Performix Super Strength Technology
1170 mg

Other Ingredients

Gelatin Sucrose Starch Talc Pharmaceutical Glaze Polyvinylpyrrolidone FD&C Blue 1 Lake Maltodextrin

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use: Adults take 1 serving (2 capsules) in the morning on an empty stomach. To assess your tolerance, start with 1/2 serving (1 capsule) and work up to the full dose. Do not exceed one (1) serving per day. This product should not be taken in combination with other products containing caffeine or other stimulants. Do not take within six hours of bedtime. Please read the entire label before use.

🧪 Formulation Notes

Super strength technology Timed-release Energy Metabolism Focus

Made in the USA

Additional Information

20 day supply

cGMP Good Manufacturing Practice

Product Details

DSLD Entry Date 2022-04-11
Product Type Other Combinations
Form Capsule
Brand Performix
DSLD ID 265515
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →